Literature DB >> 9407099

Diverse effects of BCL3 phosphorylation on its modulation of NF-kappaB p52 homodimer binding to DNA.

D L Bundy1, T W McKeithan.   

Abstract

IkappaB proteins control the subcellular localization and DNA binding activity of NF-kappaB transcription factors. BCL3 is a nuclear IkappaB that can inhibit or enhance the binding of NF-kappaB p50 or p52 homodimers to consensus DNA-binding (kappaB) sequences or form a kappaB-binding complex with homodimers. To study BCL3 function, we have used gel shift analysis and tagged protein and tagged DNA coprecipitation analyses. Our results show that at intermediate ratios of BCL3 to p52 all observed phosphoforms of BCL3 are able to form a kappaB-binding complex with p52 homodimers. At low BCL3/p52 ratios, BCL3 increases the rate of p52 homodimer binding to kappaB sites in the presence of nonconsensus DNA and dissociates from the complex. At high BCL3/p52 ratios, BCL3 forms a higher order inhibitory complex with p52 homodimers. All of these effects depend on BCL3 phosphorylation and relative concentration. These results indicate that BCL3 phosphorylation may affect its regulation of NF-kappaB-dependent transcription in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9407099     DOI: 10.1074/jbc.272.52.33132

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Crystal structure of the ankyrin repeat domain of Bcl-3: a unique member of the IkappaB protein family.

Authors:  F Michel; M Soler-Lopez; C Petosa; P Cramer; U Siebenlist; C W Müller
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

Review 2.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

Review 3.  Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma.

Authors:  Hitoshi Ohno; Momoko Nishikori; Yoshitomo Maesako; Hironori Haga
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

Review 4.  The NF-kappaB family of transcription factors and its regulation.

Authors:  Andrea Oeckinghaus; Sankar Ghosh
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10       Impact factor: 10.005

5.  A role for the IkappaB family member Bcl-3 in the control of central immunologic tolerance.

Authors:  Xiaoren Zhang; Hongshan Wang; Estefania Claudio; Keith Brown; Ulrich Siebenlist
Journal:  Immunity       Date:  2007-09       Impact factor: 31.745

6.  The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.

Authors:  Yue Zou; Mohammad M Uddin; Sveta Padmanabhan; Yan Zhu; Pengli Bu; Ales Vancura; Ivana Vancurova
Journal:  J Biol Chem       Date:  2018-08-22       Impact factor: 5.157

7.  Gene array analysis reveals changes in peripheral nervous system gene expression following stimuli that result in reactivation of latent herpes simplex virus type 1: induction of transcription factor Bcl-3.

Authors:  D Tsavachidou; W Podrzucki; J Seykora; S L Berger
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

8.  Bcl3 interacts cooperatively with peroxisome proliferator-activated receptor gamma (PPARgamma) coactivator 1alpha to coactivate nuclear receptors estrogen-related receptor alpha and PPARalpha.

Authors:  John Yang; R Sanders Williams; Daniel P Kelly
Journal:  Mol Cell Biol       Date:  2009-05-18       Impact factor: 4.272

9.  A novel role for IkappaBzeta in the regulation of IFNgamma production.

Authors:  Raquel M Raices; Yashaswini Kannan; Vedavathi Bellamkonda-Athmaram; Sudarshan Seshadri; Huating Wang; Denis C Guttridge; Mark D Wewers
Journal:  PLoS One       Date:  2009-08-26       Impact factor: 3.240

10.  Impaired TNFalpha-induced A20 expression in E1A/Ras-transformed cells.

Authors:  H-L Huang; W-C Yeh; M-Z Lai; C Mirtsos; H Chau; C-H Chou; S Benchimol
Journal:  Br J Cancer       Date:  2009-10-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.